Suppr超能文献

APOBEC3F 对原发性淋巴细胞中 HIV-1 复制的适度影响。

Moderate influence of human APOBEC3F on HIV-1 replication in primary lymphocytes.

机构信息

Mount Sinai School of Medicine, Department of Medicine, The Global Health and Emerging Pathogens Institute, New York, New York 10029, USA.

出版信息

J Virol. 2010 Sep;84(18):9613-7. doi: 10.1128/JVI.02630-09. Epub 2010 Jun 30.

Abstract

Multiple APOBEC3 proteins are expressed in HIV-1 target cells, but their individual contributions to viral suppression when expressed at endogenous levels remain largely unknown. We used an HIV NL4-3 mutant that selectively counteracts APOBEC3G (A3G) but not APOBEC3F (A3F) to dissect the relative contribution of A3F to the inhibition of HIV-1 replication in primary human lymphocytes (peripheral blood mononuclear cells [PBMCs]). This HIV Vif mutant replicated similarly to wild-type virus in PBMCs, suggesting that the effect of A3F on HIV restriction in these cells is limited. The different A3F variants found in PMBC donors displayed either comparable activity or less activity than wild-type A3F. Lastly, the endogenous A3F mRNA and protein expression levels in PBMCs were considerably lower than those of A3G. Our results suggest that A3F neutralization is dispensable for HIV-1 replication in primary human T-lymphocytes.

摘要

多种 APOBEC3 蛋白在 HIV-1 靶细胞中表达,但它们在表达内源水平时对病毒抑制的个体贡献在很大程度上仍不清楚。我们使用了一种 HIV NL4-3 突变体,该突变体能选择性地抵抗 APOBEC3G(A3G)而不是 APOBEC3F(A3F),从而剖析 A3F 对原发性人淋巴细胞(外周血单核细胞[PBMC])中 HIV-1 复制的抑制作用。这种 HIV Vif 突变体在 PBMC 中的复制与野生型病毒相似,表明 A3F 对这些细胞中 HIV 限制的作用有限。在 PMBC 供体中发现的不同 A3F 变体表现出与野生型 A3F 相当的活性或较低的活性。最后,PBMC 中内源性 A3F mRNA 和蛋白表达水平明显低于 A3G。我们的研究结果表明,A3F 中和对于原发性人 T 淋巴细胞中的 HIV-1 复制是可有可无的。

相似文献

1
Moderate influence of human APOBEC3F on HIV-1 replication in primary lymphocytes.
J Virol. 2010 Sep;84(18):9613-7. doi: 10.1128/JVI.02630-09. Epub 2010 Jun 30.
3
Mechanism of Enhanced HIV Restriction by Virion Coencapsidated Cytidine Deaminases APOBEC3F and APOBEC3G.
J Virol. 2017 Jan 18;91(3). doi: 10.1128/JVI.02230-16. Print 2017 Feb 1.
4
APOBEC3G and APOBEC3F Act in Concert To Extinguish HIV-1 Replication.
J Virol. 2016 Apr 14;90(9):4681-4695. doi: 10.1128/JVI.03275-15. Print 2016 May.
5
APOBEC3G and APOBEC3F require an endogenous cofactor to block HIV-1 replication.
PLoS Pathog. 2008 Jul 4;4(7):e1000095. doi: 10.1371/journal.ppat.1000095.
7
Long-term restriction by APOBEC3F selects human immunodeficiency virus type 1 variants with restored Vif function.
J Virol. 2010 Oct;84(19):10209-19. doi: 10.1128/JVI.00632-10. Epub 2010 Aug 4.
9
10
Regulation of Apobec3F and human immunodeficiency virus type 1 Vif by Vif-Cul5-ElonB/C E3 ubiquitin ligase.
J Virol. 2005 Aug;79(15):9579-87. doi: 10.1128/JVI.79.15.9579-9587.2005.

引用本文的文献

1
APOBEC3-Related Editing and Non-Editing Determinants of HIV-1 and HTLV-1 Restriction.
Int J Mol Sci. 2025 Feb 12;26(4):1561. doi: 10.3390/ijms26041561.
3
Retroviral Restriction Factors and Their Viral Targets: Restriction Strategies and Evolutionary Adaptations.
Microorganisms. 2020 Dec 11;8(12):1965. doi: 10.3390/microorganisms8121965.
4
Authentication Analysis of MT-4 Cells Distributed by the National Institutes of Health AIDS Reagent Program.
J Virol. 2019 Nov 26;93(24). doi: 10.1128/JVI.01390-19. Print 2019 Dec 15.
5
ARIH2 Is a Vif-Dependent Regulator of CUL5-Mediated APOBEC3G Degradation in HIV Infection.
Cell Host Microbe. 2019 Jul 10;26(1):86-99.e7. doi: 10.1016/j.chom.2019.05.008. Epub 2019 Jun 25.
6
Role of co-expressed APOBEC3F and APOBEC3G in inducing HIV-1 drug resistance.
Heliyon. 2019 Apr 16;5(4):e01498. doi: 10.1016/j.heliyon.2019.e01498. eCollection 2019 Apr.
8
Multiple Inhibitory Factors Act in the Late Phase of HIV-1 Replication: a Systematic Review of the Literature.
Microbiol Mol Biol Rev. 2018 Jan 10;82(1). doi: 10.1128/MMBR.00051-17. Print 2018 Mar.
9
HIV-1 competition experiments in humanized mice show that APOBEC3H imposes selective pressure and promotes virus adaptation.
PLoS Pathog. 2017 May 5;13(5):e1006348. doi: 10.1371/journal.ppat.1006348. eCollection 2017 May.

本文引用的文献

1
APOBEC3G contributes to HIV-1 variation through sublethal mutagenesis.
J Virol. 2010 Jul;84(14):7396-404. doi: 10.1128/JVI.00056-10. Epub 2010 May 12.
2
Quantitative profiling of the full APOBEC3 mRNA repertoire in lymphocytes and tissues: implications for HIV-1 restriction.
Nucleic Acids Res. 2010 Jul;38(13):4274-84. doi: 10.1093/nar/gkq174. Epub 2010 Mar 22.
3
Multiple ways of targeting APOBEC3-virion infectivity factor interactions for anti-HIV-1 drug development.
Trends Pharmacol Sci. 2009 Dec;30(12):638-46. doi: 10.1016/j.tips.2009.09.006.
4
Defining APOBEC3 expression patterns in human tissues and hematopoietic cell subsets.
J Virol. 2009 Sep;83(18):9474-85. doi: 10.1128/JVI.01089-09. Epub 2009 Jul 8.
6
Polymorphisms and splice variants influence the antiretroviral activity of human APOBEC3H.
J Virol. 2009 Jan;83(1):295-303. doi: 10.1128/JVI.01665-08. Epub 2008 Oct 22.
7
Sole copy of Z2-type human cytidine deaminase APOBEC3H has inhibitory activity against retrotransposons and HIV-1.
FASEB J. 2009 Jan;23(1):279-87. doi: 10.1096/fj.07-088781. Epub 2008 Sep 30.
8
Antiretroelement activity of APOBEC3H was lost twice in recent human evolution.
Cell Host Microbe. 2008 Sep 11;4(3):249-59. doi: 10.1016/j.chom.2008.07.005.
9
Characterization of conserved motifs in HIV-1 Vif required for APOBEC3G and APOBEC3F interaction.
J Mol Biol. 2008 Sep 12;381(4):1000-11. doi: 10.1016/j.jmb.2008.06.061. Epub 2008 Jun 28.
10
HIV-1 Vif, APOBEC, and intrinsic immunity.
Retrovirology. 2008 Jun 24;5:51. doi: 10.1186/1742-4690-5-51.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验